APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis (MS) Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

Multiple Sclerosis (MS) Drugs Industry Research Report 2026

26 December 2025130 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis (MS) Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis (MS) Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis (MS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis (MS) Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis (MS) Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis (MS) Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Multiple Sclerosis (MS) Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis (MS) Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Multiple Sclerosis (MS) Drugs include Eli Lilly, Bayer AG, Innate Immunotherapeutics, Gw Pharmaceuticals, Glaxosmithkline, Genzyme, Genmab, Five Prime Therapeutics and Fast Forward Llc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Multiple Sclerosis (MS) Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Multiple Sclerosis (MS) Drugs Market by Company

Eli Lilly

Bayer AG

Innate Immunotherapeutics

Gw Pharmaceuticals

Glaxosmithkline

Genzyme

Genmab

Five Prime Therapeutics

Fast Forward Llc

Daiichi Sankyo

Cinnagen

Biogen Idec

Bayhill Therapeutics

Artielle Immunotherapeutics

Apitope

Antisense Therapeutics

Multiple Sclerosis (MS) Drugs Segment by Type

Copaxone (Glatiramer Acetate, Copolymer 1)

Firategrast (Sb683699, T-0047)

Gilenya (Fingolimod, Fty720)

Tecfidera (Dimethyl Fumarate)

Aubagio (Teriflunomide)

Siponimod (Baf312)

Novantrone (Mitoxantrone)

Others

Multiple Sclerosis (MS) Drugs Segment by Application

PPMS

PRMS

RRMS

SPMS

Multiple Sclerosis (MS) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis (MS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis (MS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis (MS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Multiple Sclerosis (MS) Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Multiple Sclerosis (MS) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Multiple Sclerosis (MS) Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Multiple Sclerosis (MS) Drugs Sales (W Units) of Manufacturers (2021-2026) Table 7. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global Multiple Sclerosis (MS) Drugs Revenue of Manufacturers (2021-2026) Table 9. Global Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Multiple Sclerosis (MS) Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Multiple Sclerosis (MS) Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Multiple Sclerosis (MS) Drugs, Product Type & Application Table 14. Global Multiple Sclerosis (MS) Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Multiple Sclerosis (MS) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Eli Lilly Company Information Table 19. Eli Lilly Business Overview Table 20. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio Table 22. Eli Lilly Recent Developments Table 23. Bayer AG Company Information Table 24. Bayer AG Business Overview Table 25. Bayer AG Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio Table 27. Bayer AG Recent Developments Table 28. Innate Immunotherapeutics Company Information Table 29. Innate Immunotherapeutics Business Overview Table 30. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 32. Innate Immunotherapeutics Recent Developments Table 33. Gw Pharmaceuticals Company Information Table 34. Gw Pharmaceuticals Business Overview Table 35. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio Table 37. Gw Pharmaceuticals Recent Developments Table 38. Glaxosmithkline Company Information Table 39. Glaxosmithkline Business Overview Table 40. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio Table 42. Glaxosmithkline Recent Developments Table 43. Genzyme Company Information Table 44. Genzyme Business Overview Table 45. Genzyme Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio Table 47. Genzyme Recent Developments Table 48. Genmab Company Information Table 49. Genmab Business Overview Table 50. Genmab Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Genmab Multiple Sclerosis (MS) Drugs Product Portfolio Table 52. Genmab Recent Developments Table 53. Five Prime Therapeutics Company Information Table 54. Five Prime Therapeutics Business Overview Table 55. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 57. Five Prime Therapeutics Recent Developments Table 58. Fast Forward Llc Company Information Table 59. Fast Forward Llc Business Overview Table 60. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio Table 62. Fast Forward Llc Recent Developments Table 63. Daiichi Sankyo Company Information Table 64. Daiichi Sankyo Business Overview Table 65. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio Table 67. Daiichi Sankyo Recent Developments Table 68. Cinnagen Company Information Table 69. Cinnagen Business Overview Table 70. Cinnagen Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio Table 72. Cinnagen Recent Developments Table 73. Biogen Idec Company Information Table 74. Biogen Idec Business Overview Table 75. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio Table 77. Biogen Idec Recent Developments Table 78. Bayhill Therapeutics Company Information Table 79. Bayhill Therapeutics Business Overview Table 80. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 82. Bayhill Therapeutics Recent Developments Table 83. Artielle Immunotherapeutics Company Information Table 84. Artielle Immunotherapeutics Business Overview Table 85. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 87. Artielle Immunotherapeutics Recent Developments Table 88. Apitope Company Information Table 89. Apitope Business Overview Table 90. Apitope Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Apitope Multiple Sclerosis (MS) Drugs Product Portfolio Table 92. Apitope Recent Developments Table 93. Antisense Therapeutics Company Information Table 94. Antisense Therapeutics Business Overview Table 95. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 97. Antisense Therapeutics Recent Developments Table 98. Global Multiple Sclerosis (MS) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026) & (W Units) Table 100. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2021-2026) Table 101. Global Multiple Sclerosis (MS) Drugs Sales by Region (2027-2032) & (W Units) Table 102. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2027-2032) Table 103. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2021-2026) Table 105. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2027-2032) Table 107. North America Multiple Sclerosis (MS) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 109. North America Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 110. North America Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Multiple Sclerosis (MS) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Multiple Sclerosis (MS) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 114. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 115. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 119. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 120. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Multiple Sclerosis (MS) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 124. South America Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 125. South America Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Multiple Sclerosis (MS) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 129. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 130. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 133. Global Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 134. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2026) Table 135. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2027-2032) Table 136. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2026) Table 139. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2027-2032) Table 140. Global Multiple Sclerosis (MS) Drugs Price by Type (2021-2026) & (US$/Unit) Table 141. Global Multiple Sclerosis (MS) Drugs Price by Type (2027-2032) & (US$/Unit) Table 142. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 143. Global Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 144. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2026) Table 145. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2027-2032) Table 146. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2026) Table 149. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2027-2032) Table 150. Global Multiple Sclerosis (MS) Drugs Price by Application (2021-2026) & (US$/Unit) Table 151. Global Multiple Sclerosis (MS) Drugs Price by Application (2027-2032) & (US$/Unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Multiple Sclerosis (MS) Drugs Distributors List Table 155. Multiple Sclerosis (MS) Drugs Customers List Table 156. Multiple Sclerosis (MS) Drugs Industry Trends Table 157. Multiple Sclerosis (MS) Drugs Industry Drivers Table 158. Multiple Sclerosis (MS) Drugs Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Multiple Sclerosis (MS) Drugs Product Image Figure 5. Global Multiple Sclerosis (MS) Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Multiple Sclerosis (MS) Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global Multiple Sclerosis (MS) Drugs Sales (2021-2032) & (W Units) Figure 8. Global Multiple Sclerosis (MS) Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. Copaxone (Glatiramer Acetate, Copolymer 1) Product Image Figure 10. Firategrast (Sb683699, T-0047) Product Image Figure 11. Gilenya (Fingolimod, Fty720) Product Image Figure 12. Tecfidera (Dimethyl Fumarate) Product Image Figure 13. Aubagio (Teriflunomide) Product Image Figure 14. Siponimod (Baf312) Product Image Figure 15. Novantrone (Mitoxantrone) Product Image Figure 16. Others Product Image Figure 17. PPMS Product Image Figure 18. PRMS Product Image Figure 19. RRMS Product Image Figure 20. SPMS Product Image Figure 21. Global Multiple Sclerosis (MS) Drugs Revenue Share by Manufacturers in 2025 Figure 22. Global Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Sites & Headquarters Figure 23. Global Top 5 and 10 Multiple Sclerosis (MS) Drugs Players Market Share by Revenue in 2025 Figure 24. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Global Multiple Sclerosis (MS) Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 26. Global Multiple Sclerosis (MS) Drugs Sales by Region in 2025 Figure 27. Global Multiple Sclerosis (MS) Drugs Revenue by Region in 2025 Figure 28. North America Multiple Sclerosis (MS) Drugs Market Size by Country in 2025 Figure 29. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 30. North America Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2021-2032) Figure 31. United States Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Canada Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Mexico Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Europe Multiple Sclerosis (MS) Drugs Market Size by Country in 2025 Figure 35. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 36. Europe Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2021-2032) Figure 37. Germany Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. France Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. U.K. Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Italy Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Russia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Spain Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Netherlands Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Switzerland Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Sweden Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. Poland Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Country in 2025 Figure 48. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 49. Asia Pacific Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2021-2032) Figure 50. China Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Japan Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South Korea Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. India Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Australia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Taiwan Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Southeast Asia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. South America Multiple Sclerosis (MS) Drugs Market Size by Country in 2025 Figure 59. South America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 60. South America Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2021-2032) Figure 61. Brazil Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Argentina Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Chile Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Colombia Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country in 2025 Figure 66. Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 67. Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Market Share by Country (2021-2032) Figure 68. Egypt Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. South Africa Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Israel Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 71. Türkiye Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 72. GCC Countries Multiple Sclerosis (MS) Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 73. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2032) Figure 74. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2032) Figure 75. Global Multiple Sclerosis (MS) Drugs Price (US$/Unit) by Type (2021-2032) Figure 76. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2032) Figure 77. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2032) Figure 78. Global Multiple Sclerosis (MS) Drugs Price (US$/Unit) by Application (2021-2032) Figure 79. Multiple Sclerosis (MS) Drugs Value Chain Figure 80. Multiple Sclerosis (MS) Drugs Production Mode & Process Figure 81. Direct Comparison with Distribution Share Figure 82. Distributors Profiles Figure 83. Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • Copaxone (Glatiramer Acetate, Copolymer 1)
  • Firategrast (Sb683699, T-0047)
  • Gilenya (Fingolimod, Fty720)
  • Tecfidera (Dimethyl Fumarate)
  • Aubagio (Teriflunomide)
  • Siponimod (Baf312)
  • Novantrone (Mitoxantrone)
  • Others
Applications
  • PPMS
  • PRMS
  • RRMS
  • SPMS
Companies covered
  • Eli Lilly
  • Bayer AG
  • Innate Immunotherapeutics
  • Gw Pharmaceuticals
  • Glaxosmithkline
  • Genzyme
  • Genmab
  • Five Prime Therapeutics
  • Fast Forward Llc
  • Daiichi Sankyo
  • Cinnagen
  • Biogen Idec
  • Bayhill Therapeutics
  • Artielle Immunotherapeutics
  • Apitope
  • Antisense Therapeutics

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Multiple Sclerosis (MS) Drugs Market Size (2021-2032)
  4. 2.2.2 Global Multiple Sclerosis (MS) Drugs Sales (2021-2032)
  5. 2.2.3 Global Multiple Sclerosis (MS) Drugs Market Average Price (2021-2032)
  6. 2.3 Multiple Sclerosis (MS) Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Copaxone (Glatiramer Acetate, Copolymer 1)
  9. 2.3.3 Firategrast (Sb683699, T-0047)
  10. 2.3.4 Gilenya (Fingolimod, Fty720)
  11. 2.3.5 Tecfidera (Dimethyl Fumarate)
  12. 2.3.6 Aubagio (Teriflunomide)
  13. 2.3.7 Siponimod (Baf312)
  14. 2.3.8 Novantrone (Mitoxantrone)
  15. 2.3.9 Others
  16. 2.4 Multiple Sclerosis (MS) Drugs by Application
  17. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  18. 2.4.2 PPMS
  19. 2.4.3 PRMS
  20. 2.4.4 RRMS
  21. 2.4.5 SPMS
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Multiple Sclerosis (MS) Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Multiple Sclerosis (MS) Drugs Sales (W Units) of Manufacturers (2021-2026)
  3. 3.3 Global Multiple Sclerosis (MS) Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Multiple Sclerosis (MS) Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Multiple Sclerosis (MS) Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Multiple Sclerosis (MS) Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Multiple Sclerosis (MS) Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of Multiple Sclerosis (MS) Drugs, Established Date
  9. 3.9 Global Multiple Sclerosis (MS) Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Eli Lilly
  2. 4.1.1 Eli Lilly Company Information
  3. 4.1.2 Eli Lilly Business Overview
  4. 4.1.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
  6. 4.1.5 Eli Lilly Recent Developments
  7. 4.2 Bayer AG
  8. 4.2.1 Bayer AG Company Information
  9. 4.2.2 Bayer AG Business Overview
  10. 4.2.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
  12. 4.2.5 Bayer AG Recent Developments
  13. 4.3 Innate Immunotherapeutics
  14. 4.3.1 Innate Immunotherapeutics Company Information
  15. 4.3.2 Innate Immunotherapeutics Business Overview
  16. 4.3.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  18. 4.3.5 Innate Immunotherapeutics Recent Developments
  19. 4.4 Gw Pharmaceuticals
  20. 4.4.1 Gw Pharmaceuticals Company Information
  21. 4.4.2 Gw Pharmaceuticals Business Overview
  22. 4.4.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
  24. 4.4.5 Gw Pharmaceuticals Recent Developments
  25. 4.5 Glaxosmithkline
  26. 4.5.1 Glaxosmithkline Company Information
  27. 4.5.2 Glaxosmithkline Business Overview
  28. 4.5.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
  30. 4.5.5 Glaxosmithkline Recent Developments
  31. 4.6 Genzyme
  32. 4.6.1 Genzyme Company Information
  33. 4.6.2 Genzyme Business Overview
  34. 4.6.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
  36. 4.6.5 Genzyme Recent Developments
  37. 4.7 Genmab
  38. 4.7.1 Genmab Company Information
  39. 4.7.2 Genmab Business Overview
  40. 4.7.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
  42. 4.7.5 Genmab Recent Developments
  43. 4.8 Five Prime Therapeutics
  44. 4.8.1 Five Prime Therapeutics Company Information
  45. 4.8.2 Five Prime Therapeutics Business Overview
  46. 4.8.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  48. 4.8.5 Five Prime Therapeutics Recent Developments
  49. 4.9 Fast Forward Llc
  50. 4.9.1 Fast Forward Llc Company Information
  51. 4.9.2 Fast Forward Llc Business Overview
  52. 4.9.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
  54. 4.9.5 Fast Forward Llc Recent Developments
  55. 4.10 Daiichi Sankyo
  56. 4.10.1 Daiichi Sankyo Company Information
  57. 4.10.2 Daiichi Sankyo Business Overview
  58. 4.10.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
  60. 4.10.5 Daiichi Sankyo Recent Developments
  61. 4.11 Cinnagen
  62. 4.11.1 Cinnagen Company Information
  63. 4.11.2 Cinnagen Business Overview
  64. 4.11.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
  66. 4.11.5 Cinnagen Recent Developments
  67. 4.12 Biogen Idec
  68. 4.12.1 Biogen Idec Company Information
  69. 4.12.2 Biogen Idec Business Overview
  70. 4.12.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
  72. 4.12.5 Biogen Idec Recent Developments
  73. 4.13 Bayhill Therapeutics
  74. 4.13.1 Bayhill Therapeutics Company Information
  75. 4.13.2 Bayhill Therapeutics Business Overview
  76. 4.13.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  78. 4.13.5 Bayhill Therapeutics Recent Developments
  79. 4.14 Artielle Immunotherapeutics
  80. 4.14.1 Artielle Immunotherapeutics Company Information
  81. 4.14.2 Artielle Immunotherapeutics Business Overview
  82. 4.14.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  84. 4.14.5 Artielle Immunotherapeutics Recent Developments
  85. 4.15 Apitope
  86. 4.15.1 Apitope Company Information
  87. 4.15.2 Apitope Business Overview
  88. 4.15.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
  90. 4.15.5 Apitope Recent Developments
  91. 4.16 Antisense Therapeutics
  92. 4.16.1 Antisense Therapeutics Company Information
  93. 4.16.2 Antisense Therapeutics Business Overview
  94. 4.16.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  96. 4.16.5 Antisense Therapeutics Recent Developments
5 Global Multiple Sclerosis (MS) Drugs Market Scenario by Region
  1. 5.1 Global Multiple Sclerosis (MS) Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2027-2032
  5. 5.3 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2027-2032
  8. 5.4 North America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
  9. 5.4.1 North America Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
  41. 5.7.1 South America Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.7.7 Colombia
  48. 5.8 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Facts & Figures by Country
  49. 5.8.1 Middle East and Africa Multiple Sclerosis (MS) Drugs Market Size by Country: 2021 VS 2025 VS 2032
  50. 5.8.2 Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  51. 5.8.3 Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue by Country (2021-2032)
  52. 5.8.4 Egypt
  53. 5.8.5 South Africa
  54. 5.8.6 Israel
  55. 5.8.7 Türkiye
  56. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032) & (W Units)
  3. 6.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Multiple Sclerosis (MS) Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032) & (W Units)
  3. 7.1.2 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Multiple Sclerosis (MS) Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Multiple Sclerosis (MS) Drugs Value Chain Analysis
  2. 8.1.1 Multiple Sclerosis (MS) Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Multiple Sclerosis (MS) Drugs Production Mode & Process
  5. 8.2 Multiple Sclerosis (MS) Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Multiple Sclerosis (MS) Drugs Distributors
  8. 8.2.3 Multiple Sclerosis (MS) Drugs Customers
9 Global Multiple Sclerosis (MS) Drugs Analyzing Market Dynamics
  1. 9.1 Multiple Sclerosis (MS) Drugs Industry Trends
  2. 9.2 Multiple Sclerosis (MS) Drugs Industry Drivers
  3. 9.3 Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges
  4. 9.4 Multiple Sclerosis (MS) Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst